How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Depression is the single largest contributor to non-fatal health loss and affects 322 million people globally. The clinical heterogeneity of this disorder shows biological correlates and it makes the personalization of antidepressant prescription an important pillar of treatment. There is increasing evidence of genetic overlap between depression, other psychiatric and non-psychiatric disorders, which varies across depression subtypes. Therefore, the first step of clinical evaluation should include a careful assessment of psychopathology and physical health, not limited to previously diagnosed disorders. In part of the patients indeed the pathogenesis of depression may be strictly linked to inflammatory and metabolic abnormalities, and the treatment should target these as much as the depressive symptoms themselves. When the evaluation of the symptom and drug tolerability profile, the concomitant biochemical abnormalities and physical conditions is not enough and at least one pharmacotherapy failed, the genotyping of variants in CYP2D6/CYP2C19 (cytochromes responsible for antidepressant metabolism) should be considered. Individuals with altered metabolism through one of these enzymes may benefit from some antidepressants rather than others or need dose adjustments. Finally, if available, the polygenic predisposition towards cardio-metabolic disorders can be integrated with non-genetic risk factors to tune the identification of patients who should avoid medications associated with this type of side effects. A sufficient knowledge of the polygenic risk of complex medical and psychiatric conditions is becoming relevant as this information can be obtained through direct-to-consumer genetic tests and in the future it may provided by national health care systems.
Abstract
Depression is the single largest contributor to non-fatal health loss and affects 322 million people globally. The clinical heterogeneity of this disorder shows biological correlates and it makes the personalization of antidepressant prescription an important pillar of treatment. There is increasing evidence of genetic overlap between depression, other psychiatric and non-psychiatric disorders, which varies across depression subtypes. Therefore, the first step of clinical evaluation should include a careful assessment of psychopathology and physical health, not limited to previously diagnosed disorders. In part of the patients indeed the pathogenesis of depression may be strictly linked to inflammatory and metabolic abnormalities, and the treatment should target these as much as the depressive symptoms themselves. When the evaluation of the symptom and drug tolerability profile, the concomitant biochemical abnormalities and physical conditions is not enough and at least one pharmacotherapy failed, the genotyping of variants in CYP2D6/CYP2C19 (cytochromes responsible for antidepressant metabolism) should be considered. Individuals with altered metabolism through one of these enzymes may benefit from some antidepressants rather than others or need dose adjustments. Finally, if available, the polygenic predisposition towards cardio-metabolic disorders can be integrated with non-genetic risk factors to tune the identification of patients who should avoid medications associated with this type of side effects. A sufficient knowledge of the polygenic risk of complex medical and psychiatric conditions is becoming relevant as this information can be obtained through direct-to-consumer genetic tests and in the future it may provided by national health care systems.
참고문헌 (51)
- "Depression and other common mental disorders: global health estimates" (2017)[URL]
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
- Huynh NN, "What are the implications of the STAR*D trial for primary care? A review and synthesis", Prim Care Companion J Clin Psychiatry, 10, pp.91~96 (2008)
- Gaynes BN, "What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression", Psychiatr Serv, 60, pp.1439~1445 (2009)
- Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
- Pain O, "Investigating the common genetic basis of antidepressant response", 27th World Congress of Psychiatric Genetics (WCPG), pp.S91~S92 (2019)
- Isabella Badini, "Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption", Psychological Medicine, pp.1~11 (2020), Cambridge University Press (CUP)[DOI]
- Milaneschi Y, "Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations", JAMA Psychiatry, 74, pp.1214~1225 (2017)
- Milaneschi Y, "Polygenic dissection of major depression clinical heterogeneity", Mol Psychiatry, 21, pp.516~522 (2016)
- "Genetic Testing Statement" (2019)[URL]
- "The ultimate guide on how to offer genetic testing services or boost your current offerings in no time" (2019)[URL]
- Taylor DM, "The Maudsley prescribing guidelines in psychiatry" (2018), Wiley-Blackwell
- Nihalani N, "Weight gain, obesity, and psychotropic prescribing", J Obes, 2011, pp.893629~ (2011)
- Tyrrell J, "Using genetics to understand the causal influence of higher BMI on depression", Int J Epidemiol, 48, pp.834~848 (2019)
- Rizvi SJ, "Treatment-resistant depression in primary care across Canada", Can J Psychiatry, 59, pp.349~357 (2014)
- Kemp DE, "PPAR- γagonism as a modulator of mood: proofof-concept for pioglitazone in bipolar depression", CNS Drugs, 28, pp.571~581 (2014)
- Colle R, "PPAR- γagonists for the treatment of major depression:a review", Pharmacopsychiatry, 50, pp.49~55 (2017)
- Köhler-Forsberg O, "Do statins have antidepressant effects?", CNS Drugs, 31, pp.335~343 (2017)
- Chamberlain SR, "Treatment-resistant depression and peripheral C-reactive protein", Br J Psychiatry, 214, pp.11~19 (2019)
- Jha MK, "Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial", Psychoneuroendocrinology, 78, pp.105~113 (2017)
- Jha MK, "Personalized antidepressant selection and pathway to novel treatments : clinical utility of targeting inflammation", Int J Mol Sci, 19, pp.233~ (2018)
- Raison CL, "A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression : the role of baseline inflammatory biomarkers", JAMA Psychiatry, 70, pp.31~41 (2013)
- Giampaolo Perna, "Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables", PSYCHIATRY INVESTIGATION, 17(3), pp.193~206 (2020), 대한신경정신의학회[DOI]
- Ward J, "Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure", Transl Psychiatry, 9, pp.327~ (2019)
- Jackson G. Thorp, "Genetic heterogeneity in self-reported depressive symptoms identified through genetic analyses of the PHQ-9", Psychological Medicine, 50(14), pp.2385~2396 (2020), Cambridge University Press (CUP)[DOI]
- "Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder" (2020)[URL]
- DeVido JJ, "Treatment of the depressed alcoholic patient", Curr Psychiatry Rep, 14, pp.610~618 (2012)
- Marmorstein NR, "Associations between subtypes of major depressive episodes and substance use disorders", Psychiatry Res, 186, pp.248~253 (2011)
- Leventhal AM, "Associations between depression subtypes and substance use disorders", Psychiatry Res, 161, pp.43~50 (2008)
- Brailean A, "Characteristics, comorbidities, and correlates of atypical depression : evidence from the UK Biobank Mental Health Survey", Psychol Med, 50, pp.1129~1138 (2020)
- Kranzler HR, "Genome-wide association study of alcohol consumption and use disorder in 274, 424 individuals from multiple populations", Nat Commun, 10, pp.1499~ (2019)
- "Clinical guideline annotations" (2020)[URL]
- Porcelli S, "Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism", Expert Opin Drug Metab Toxicol, 7, pp.1101~1115 (2011)
- Fabbri C, "Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects : meta-analysis of data from genome-wide association studies", Eur Neuropsychopharmacol, 28, pp.945~954 (2018)
- Howland RH, "A critical evaluation of the cardiac toxicity of citalopram : part 1", J Psychosoc Nurs Ment Health Serv, 49, pp.13~16 (2011)
- Greden JF, "Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial : a large, patient-and rater-blinded, randomized, controlled study", J Psychiatr Res, 111, pp.59~67 (2019)
- Picard N, "Pharmacogenetics-based personalized therapy : levels of evidence and recommendations from the French Network of Pharmacogenetics(RNPGx)", Therapie, 72, pp.185~192 (2017)
- Maruf AA, "Pharmacogenetic testing options relevant to psychiatry in Canada : options de tests pharmacogénétiques pertinents en psychiatrie au Canada", Can J Psychiatry, 65, pp.521~530 (2020)
- Fabbri C, "Pharmacogenetic tests to guide drug treatment in depression : comparison of the available testing kits and clinical trials", Prog Neuropsychopharmacol Biol Psychiatry, 86, pp.36~44 (2018)
- Bousman C, "Towards the integration of pharmacogenetics in psychiatry : a minimum, evidence-based genetic testing panel", Curr Opin Psychiatry, 32, pp.7~15 (2019)
- So HC, "Exploring the predictive power of polygenic scores derived from genome-wide association studies : a study of 10 complex traits", Bioinformatics, 33, pp.886~892 (2017)
- Lewis CM, "Polygenic risk scores : from research tools to clinical instruments", Genome Med, 12, pp.44~ (2020)
- Lambert SA, "Towards clinical utility of polygenic risk scores", Hum Mol Genet, 28, pp.R133~R142 (2019)
- Wu Q, "Depression and the risk of myocardial infarction and coronary death: a meta-analysis of prospective cohort studies", Medicine (Baltimore), 95, pp.e2815~ (2016)
- Holt RI, "Diabetes and depression", Curr Diab Rep, 14, pp.491~ (2014)
- Läll K, "Personalized risk prediction for type 2 diabetes : the potential of genetic risk scores", Genet Med, 19, pp.322~329 (2017)
- García-González J, "Pharmacogenetics of antidepressant response : a polygenic approach", Prog Neuropsychopharmacol Biol Psychiatry, 75, pp.128~134 (2017)
- International Consortium on Lithium Genetics(ConLi＋Gen), "Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder : a genome-wide association study", JAMA Psychiatry, 75, pp.65~74 (2018)
- Wray NR, "Genomewide association analyses identify 44 risk variants and refine the genetic architecture of major depression", Nat Genet, 50, pp.668~681 (2018)
- "The polygenic score catalog: an open database for reproducibility and systematic evaluation" (2020)[URL]
- Folkersen L, "Impute.me: an open-source, non-profit tool for using data from direct-to-consumer genetic testing to calculate and interpret polygenic risk scores", Front Genet, 11, pp.578~ (2020)